Physician profile
Jack L Brenner
NPI 1033287347
$9,615.75
in general payments reported to CMS, 2019-2025
37 companies · $1,744 in 2025
The $1,744 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $3,762 · 2021: $649 · 2022: $501 · 2023: $1,264 · 2024: $1,370 · 2025: $1,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,377.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Planmeca USA, INC. | $3,475.56 | 2020 | |
| Abbvie INC. | $1,711.37 | 2019-2025 | Ubrelvy, Qulipta, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $840.45 | 2020-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $481.21 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $471.84 | 2019-2025 | Entyvio, Trintellix |
| Novo Nordisk INC | $450.17 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Scientific Affairs, LLC | $198.91 | 2022-2023 | Xarelto |
| Celgene Corporation | $168.71 | 2021-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $143.65 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.77 | 2023-2025 | |
| Glaxosmithkline, LLC. | $122.19 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $111.73 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $103.39 | 2025 | Zenpep |
| Pfizer INC. | $102.06 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $99.02 | 2023-2024 | Xarelto |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Brenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.